TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy-EGFR mutated non-small cell lung cancer IV patients treated with osimertinib. - Roeper J; Christopoulos P; Falk M; Heukamp LC; Tiemann M; Stenzinger A; Thomas M; Griesinger F (Translational lung cancer research, 2022)